Lexaria Bioscience Corp

0.2351

-0.0049-2.04%

Volume:10.39K

Turnover:2.45K

Market Cap:1.20M

PE:- -

High:0.2370

Open:0.2360

Low:0.2014

Close:0.2400

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

ACCESS Newswire

·

27 Feb

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LEXXW"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LEXXW"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LEXXW\",,,,,undefined,":{"symbol":"LEXXW","market":"US","secType":"STK","nameCN":"Lexaria Bioscience Corp","latestPrice":0.2351,"timestamp":1741809600000,"preClose":0.24,"halted":0,"volume":10388,"delay":0,"changeRate":-0.020417,"change":-0.0049,"floatShares":5104300,"shares":5104300,"lyrEps":0,"pbRate":0.12,"amount":2450.4712,"amplitude":0.148333,"volumeRatio":5.80335143657194,"dividePrice":0,"prevYearClose":0.7641,"fiveDayClose":0.2388,"twentyDayClose":0.22},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LEXXW\",,,,,undefined,":{"symbol":"LEXXW","floatShares":5104300,"roa":"-67.50%","roe":"-114.83%","lyrEps":0,"volumeRatio":5.80335143657194,"shares":5104300,"dividePrice":0,"high":0.237,"amplitude":0.148333,"preClose":0.24,"low":0.2014,"week52Low":0.16,"pbRate":"0.12","psRate":"2.41","week52High":2.07,"institutionHeld":0,"latestPrice":0.2351,"eps":0,"divideRate":0,"volume":10388,"delay":0,"ttmEps":0,"open":0.236,"prevYearClose":0.7641,"prevWeekClose":0.23,"prevMonthClose":0.249,"prevQuarterClose":0.7641,"fiveDayClose":0.2388,"twentyDayClose":0.22,"sixtyDayClose":0.705},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LEXXW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LEXXW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LEXXW\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/LEXXW\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LEXXW\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514804509","title":"The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience","url":"https://stock-news.laohu8.com/highlight/detail?id=2514804509","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514804509?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:00","pubTimestamp":1740661200,"startTime":"0","endTime":"0","summary":"Lexaria executing a triple-pronged strategy in obesity and diabetes. Semaglutide recently approved to treat chronic kidney disease. The GLP-1 industry is experiencing revolutionary advancements across multiple healthcare sectors. If there has ever been a class of drugs that could change the world - or is perhaps already changing the world - it would be GLP-1. As tens of millions of people around the world utilize these drugs in their pursuit of better health outcomes, there will of course be unwanted side effects and even negative health outcomes in some fraction of GLP-1 drug users. With that said, the benefits of these drugs overwhelmingly outweigh all of the currently known negative outcomes.As we noted on November 26, 2024, GLP-1 drugs are either approved for use, or are being investigated for use, in all of the following healthcare sectors:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/global-revolution-healthcare-driven-glp-130000643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCSG","GLP","BK4590","LEXX","BK4144","BK4137","BK4007","LEXXW"],"gpt_icon":0},{"id":"2513972986","title":"Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm","url":"https://stock-news.laohu8.com/highlight/detail?id=2513972986","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513972986?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:00","pubTimestamp":1740402000,"startTime":"0","endTime":"0","summary":"5th study arm in 12-week Phase 1b Study receives lead clinical site approval. KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee  approval that was required before dosing can begin in the 5th study arm of the Company's Phase 1b, 12-week chronic study GLP-1-H24-4,  in Australia.This news complements similar news issued on November 13, 2024, when initial lead clinical site HREC approval was received for the first 4 arms of the Study. The Company is pleased to have received all of the necessary lead clinical site approvals so quickly. Additional HREC approval is still pending for the other clinical sites, which is expected soon.The Study is progressing with both patient recruitment and dosing. The milestone of First Patient First Dose occurred in December 2024 as planned. As a reminder, the 5 Study arms are as follows:. This press release","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ethics-board-approval-received-dehydratech-130000223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLP","BK4144","BK4557","ACB","BK4590","ARM","LEXXW","LEXX","BK4007"],"gpt_icon":0},{"id":"2510385490","title":"Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2510385490","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510385490?lang=en_us&edition=fundamental","pubTime":"2025-02-11 21:00","pubTimestamp":1739278800,"startTime":"0","endTime":"0","summary":"KELOWNA, BC / ACCESS Newswire / February 11, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, is pleased to announce that we have been granted two new patents from the United States Patent and Trademark Office for the use of DehydraTECH enhanced processing technology related to the treatment of epilepsy.\"We are thrilled to have received broadened claims related to our proprietary DehydraTECH technology for the treatment of epilepsy,\" said Rich Christopher, CEO of Lexaria. \"Each of our patent awards enhances our ability to reach commercial criticality while providing enhanced value to our potential pharmaceutical partners and, ultimately, to patients.\". Lexaria has received its 5th and 6th US patents granted in its patent family #24, Compositions and Methods for Treating Epilepsy. These patents complement earlier research which indicated that DehydraTECH-CBD was capable of mitigating epileptic seizures in rodents, and was also absorbed into the bloodstre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-granted-two-dehydratech-patents-130000319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LEXXW","LEXX"],"gpt_icon":0},{"id":"2509771692","title":"Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway","url":"https://stock-news.laohu8.com/highlight/detail?id=2509771692","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509771692?lang=en_us&edition=fundamental","pubTime":"2025-02-06 22:40","pubTimestamp":1738852800,"startTime":"0","endTime":"0","summary":"World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules. KELOWNA, BC / ACCESS Newswire / February 6, 2025 / Lexaria Bioscience Corp.  , a global innovator in drug delivery platforms, announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide  rodent biodistribution study .Distribution of a drug once it enters the body can provide vital clues as to the understanding of that drug's ability to bind with targeted receptor cells, avoid concentration at physical sites that might be prone to fostering adverse side effects, and increase the drug's ultimate efficacy. Lexaria hopes to discover whether the DehydraTECH processing of semaglutide improves its biodistribution in any significant way compared to the conventional orally administered semaglutide formulation practice.DehydraTECH is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients  enter the bloodstream ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lexaria-biodistribution-study-dehydratech-glp-144000532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4590","LEXX","BK4144","GLP","LEXXW"],"gpt_icon":0}],"pageSize":4,"totalPage":8,"pageCount":1,"totalSize":31}]}}